Date: 2015-03-25
Type of information: IPO
Company: Cerenis Therapeutics (France)
Investors:
Amount: €53.4 million
Funding type: IPO
Planned used: Cerenis Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative HDL (“good cholestrol”) therapies for the treatment of cardiovascular and metabolic diseases. The funds raised will be used to support CER- 001 clinical studies. This compound mimicks the structure and functions of natural HDL to promote and stimulate the removal of excess cholesterol. The first study is a Phase II study in post acute coronary syndrome , and the second is a phase III study in patients with a genetic deficiency of HDL, with the goal of filing an application for marketing authorization by 2018.
Others: * On March 25, 2015, Cerenis Therapeutics, an international biopharmaceutical company dedicated to discovering and developing innovative HDL (“good cholestrol”) therapies for the treatment of cardiovascular and metabolic disease, announced that the company has raised €53.4 million. Cerenis Therapeutics is now listed on Euronext through the admission to trading of 17,788,878 ordinary shares making up its equity, including 4,207,316 new shares issued under a Global Offering. The admission and issue price of Cerenis Therapeutics was set at €12.70 per share, at the high end of the price range. Market capitalisation on the day of listing was €226 million.
Therapeutic area: Cardiovascular diseases - Metabolic diseases - Rare diseases
